Developed through a rigorous, multi-round survey process, the consensus guidance issued independently by the National Alopecia Areata Foundation (NAAF) and the American Hair Research Society (AHRS) reflect the collective clinical expertise of 30 leading U.S. alopecia areata specialists. The treatment recommendations were published in Journal of the American Medical Association Dermatology (JAMA Dermatology).
AA is an autoimmune disease where the body’s immune system mistakenly attacks hair follicles, leading to hair loss not only limited to the scalp, but can also affect other hair bearing body sites. Impacting an estimated 300,000 U.S. adults, severe AA causes more than hair loss; it also carries a significant physical and psychosocial burden for patients. The expert guidance adopts a standardized severity scale that goes beyond scalp hair loss percentage to include psychosocial impact, eyebrow and eyelash involvement, and prior treatment response, more accurately reflecting the challenges of living with severe AA.
/PRNewswire/ — Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524,715, together with its subsidiaries and/or affiliated companies, “Sun Pharma”) today expressed its support for the first standardized United States treatment recommendations for adults with severe alopecia areata (AA). Developed through a rigorous, multi-round survey process, the consensus guidance issued independently by the National Alopecia Areata Foundation (NAAF) and the American Hair Research Society (AHRS) reflect the collective clinical expertise of 30 leading U.S. alopecia areata specialists. The treatment recommendations were published in Journal of the American Medical Association Dermatology (JAMA Dermatology).